Loading...
•
Mar 31, 2021
Inozyme Q1 2021 Earnings Report
Inozyme Pharma reported financial results for Q1 2021 and provided business highlights.
Key Takeaways
Inozyme Pharma reported a net loss of $11.1 million for the quarter ended March 31, 2021. The company's cash, cash equivalents, and investments were $147.6 million as of March 31, 2021, which is expected to enable operations into the fourth quarter of 2022.
Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe and expects to initiate Phase 1/2 clinical trial in mid-2021.
Published peer-reviewed preclinical data supporting INZ-701 as a potential treatment for ENPP1 Deficiency in Journal of Bone and Mineral Research.
Presented data from first-ever Burden of Illness Study for ENPP1 and ABCC6 Deficiencies at multiple medical conferences.
Cash, cash equivalents, and investments expected to enable continued operations into the fourth quarter of 2022.
Forward Guidance
Inozyme Pharma expects that its existing cash, cash equivalents, and investments will be sufficient to enable funding of its operating expenses and capital expenditure requirements into the fourth quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...